Galmed Pharmaceuticals Ltd.
GLMD
$4.63
$0.8121.05%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.01% | 16.66% | 10.22% | -13.18% | 3.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.66% | 51.28% | 35.55% | 4.82% | 12.59% |
| Operating Income | -41.66% | -51.28% | -35.55% | -4.82% | -12.59% |
| Income Before Tax | -30.05% | -51.31% | -37.14% | -37.57% | -48.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.05% | -51.31% | -37.14% | -37.57% | -48.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.05% | -51.31% | -37.14% | -37.57% | -48.26% |
| EBIT | -41.66% | -51.28% | -35.55% | -4.82% | -12.59% |
| EBITDA | 27.07% | -18.81% | -36.03% | -5.29% | -13.70% |
| EPS Basic | 67.70% | 68.53% | 70.20% | 84.35% | 78.76% |
| Normalized Basic EPS | 69.01% | 72.69% | 73.69% | 86.70% | 80.25% |
| EPS Diluted | 67.70% | 68.53% | 70.20% | 84.35% | 78.76% |
| Normalized Diluted EPS | 69.01% | 72.69% | 73.69% | 86.70% | 80.25% |
| Average Basic Shares Outstanding | 214.55% | 349.73% | 362.20% | 472.72% | 388.14% |
| Average Diluted Shares Outstanding | 214.55% | 349.73% | 362.20% | 472.72% | 388.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |